CROI 2012: HIV Superinfections May Happen as Often as First Infections
- Details
- Category: HIV Sexual Transmission
- Published on Tuesday, 13 March 2012 00:00
- Written by Gus Cairns
Two studies of people with HIV in Rakai, Uganda, and Mombasa, Kenya, presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle show that the rate at which they acquired second, subsequent strains of HIV was about the same as the HIV incidence rate in the general population.
CROI 2012: HIV/HCV Coinfection News from CROI 2012 [VIDEO]
- Details
- Category: HCV Treatment
- Published on Monday, 12 March 2012 00:00
- Written by Gregory Fowler
Hepatitis C was a major topic at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle. Liz Highleyman from HIVandHepatitis.com spoke with Douglas Dieterich and Kenneth Sherman about advances in the field, with a focus on HIV/HCV coinfected patients.
The attention this year was apt, since an estimated one-third of people with HIV are coinfected with hepatitis C virus (HCV). Dieterich and Mark Sulkowski presented the first data on sustained virological response (SVR) using the recently approved HCV protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek) plus pegylated interferon/ribavirin in HIV/HCV coinfected patients.
CROI 2012: Interactions between HCV Drug Daclatasvir and HIV Antiretrovirals Are Minimal or Manageable
- Details
- Category: HCV Treatment
- Published on Friday, 09 March 2012 00:00
- Written by Liz Highleyman
The investigational hepatitis C virus (HCV) NS5A inhibitor daclatasvir (formerly BMS-790052) showed no clinically relevant effects on blood levels of 3 classes of antiretroviral agents, and changes in daclatasvir levels can likely be overcome by dose adjustment, according to a data presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.
CROI 2012: New Integrase Inhibitor Dolutegravir Still Potent and Well-Tolerated at 96 Weeks
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 09 March 2012 00:00
- Written by Liz Highleyman
The next-generation integrase inhibitor dolutegravir maintains viral suppression and remains safe after 2 years of use, according to a small study presented Wednesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.
CROI 2012: Drug Levels Predict Efficacy in PrEP Trials, Highlighting Importance of Adherence
- Details
- Category: HIV Prevention
- Published on Thursday, 08 March 2012 00:00
- Written by Paul Dalton
Two analyses of PrEP studies presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle found that drug levels -- and by implication, adherence -- were strongly correlated with protection against HIV infection.
More Articles...
- CROI 2012: Tenofovir Pro-drug GS-7340 Shows Good Efficacy, Safety, and Suitability for Coformulation
- CROI 2012: PEPFAR Funding Linked to Lower Death Rate from All Causes in Africa
- CROI 2012: Studies Advance Development of Microbicides for HIV Prevention
- CROI 2012: HIV Cure Research -- A New Era of Treatment [VIDEO]
Web Design and Development by